BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31499027)

  • 1. Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis.
    Porter CM; Haffner MC; Kulac I; Maynard JP; Baena-Del Valle JA; Isaacs WB; Yegnasubramanian S; De Marzo AM; Sfanos KS
    Am J Pathol; 2019 Nov; 189(11):2311-2322. PubMed ID: 31499027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
    Kang GH; Lee S; Lee HJ; Hwang KS
    J Pathol; 2004 Feb; 202(2):233-40. PubMed ID: 14743506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm.
    Cho NY; Kim JH; Moon KC; Kang GH
    Virchows Arch; 2009 Jan; 454(1):17-23. PubMed ID: 19048291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
    Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
    Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of Lactotransferrin expression by methylation in prostate cancer progression.
    Shaheduzzaman S; Vishwanath A; Furusato B; Cullen J; Chen Y; Bañez L; Nau M; Ravindranath L; Kim KH; Mohammed A; Chen Y; Ehrich M; Srikantan V; Sesterhenn IA; McLeod D; Vahey M; Petrovics G; Dobi A; Srivastava S
    Cancer Biol Ther; 2007 Jul; 6(7):1088-95. PubMed ID: 17568188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
    Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
    J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive Spreading of DNA Methylation in the GSTP1 Promoter CpG Island across Transitions from Precursors to Invasive Prostate Cancer.
    Gupta H; Inoue H; Nakai Y; Nakayama M; Jones T; Hicks JL; Kumar B; Gurel M; Nelson WG; De Marzo AM; Yegnasubramanian S
    Cancer Prev Res (Phila); 2023 Aug; 16(8):449-460. PubMed ID: 37347938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers.
    Sidiropoulos M; Pampalakis G; Sotiropoulou G; Katsaros D; Diamandis EP
    Tumour Biol; 2005; 26(6):324-36. PubMed ID: 16254462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity.
    Yegnasubramanian S; Haffner MC; Zhang Y; Gurel B; Cornish TC; Wu Z; Irizarry RA; Morgan J; Hicks J; DeWeese TL; Isaacs WB; Bova GS; De Marzo AM; Nelson WG
    Cancer Res; 2008 Nov; 68(21):8954-67. PubMed ID: 18974140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection.
    Nakayama M; Bennett CJ; Hicks JL; Epstein JI; Platz EA; Nelson WG; De Marzo AM
    Am J Pathol; 2003 Sep; 163(3):923-33. PubMed ID: 12937133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypermethylation of the caveolin-1 gene promoter in prostate cancer.
    Cui J; Rohr LR; Swanson G; Speights VO; Maxwell T; Brothman AR
    Prostate; 2001 Feb; 46(3):249-56. PubMed ID: 11170154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
    Lee J; Lee MS; Jeoung DI; Kim YM; Lee H
    Prostate; 2017 Mar; 77(4):350-360. PubMed ID: 27813113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermethylation of CpG islands in primary and metastatic human prostate cancer.
    Yegnasubramanian S; Kowalski J; Gonzalgo ML; Zahurak M; Piantadosi S; Walsh PC; Bova GS; De Marzo AM; Isaacs WB; Nelson WG
    Cancer Res; 2004 Mar; 64(6):1975-86. PubMed ID: 15026333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
    Sørensen KD; Borre M; Ørntoft TF; Dyrskjøt L; Tørring N
    Int J Cancer; 2008 Feb; 122(3):509-19. PubMed ID: 17943724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer.
    Nakayama M; Gonzalgo ML; Yegnasubramanian S; Lin X; De Marzo AM; Nelson WG
    J Cell Biochem; 2004 Feb; 91(3):540-52. PubMed ID: 14755684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant Hypermethylation-Mediated Suppression of PYCARD Is Extremely Frequent in Prostate Cancer with Gleason Score ≥ 7.
    Miyauchi T; Takahashi M; Mitsuzuka K; Saiki Y; Okubo T; Vertino PM; Goto A; Arai Y; Horii A; Fukushige S
    Dis Markers; 2021; 2021():8858905. PubMed ID: 33628338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetically Silenced Candidate Tumor Suppressor Genes in Prostate Cancer: Identified by Modeling Methylation Stratification and Applied to Progression Prediction.
    Zhang W; Flemington EK; Deng HW; Zhang K
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):198-207. PubMed ID: 30262601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma.
    Yi HM; Li H; Peng D; Zhang HJ; Wang L; Zhao M; Yao KT; Ren CP
    Oncol Res; 2006; 16(6):261-72. PubMed ID: 17476971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-expression of Lactotransferrin, a candidate tumor suppressor inactivated by promoter hypermethylation, impairs the malignance of oral squamous cell carcinoma cells.
    Zhang J; Ling T; Wu H; Wang K
    J Oral Pathol Med; 2015 Sep; 44(8):578-84. PubMed ID: 25370482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.